Inhibitors of vascular endothelial growth factor (VEGF) in the management of neovascular age‐related macular degeneration: a review of current practice

REFERENCES

• Van newkirk MR, Nanjan MB, Wang JJ, Mitchell P, Taylor HR, Mccarty CA. The prevalence of age‐related maculopathy: The Visual Impairment Project. Ophthalmology 2000; 107: 1593–1600.
   Web of Science ®Google Scholar
• Access Economics and Eye Research Australia. Clear Insight: The economic impact and cost of vision loss in Australia. 2004. http://cera.unimelb.edu.au/publications/reports/access/clearinsight.pdf (accessed 20 December, 2007).
   Google Scholar
• Mitchell P, Smith W, Attebo K, Wang JJ. Prevalence of age‐related maculopathy in Australia. The Blue Mountains Eye Study. Ophthalmology 1995; 102: 1450–1460.
   PubMed Web of Science ®Google Scholar
• Taylor HR, Keeffe JE, Vu HTV, Wang JJ, Rochtchina E, Pezzullo ML, Mitchell P. Vision loss in Australia. Med J Aust 2005; 182: 565–568.
   PubMed Web of Science ®Google Scholar
• Ferris FL, Fine SL, Hyman L. Age‐related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol 1984; 102: 1640–1642.
   PubMed Web of Science ®Google Scholar
• Virgili G, Bini A. Laser photocoagulation for neovascular age‐related macular degeneration. Cochrane Database of Systematic Reviews. 2007, Issue 3. Art. No.: CD004763. DOI: 10.1002/14651858.CD004763.pub2.
   Google Scholar
• Wormald R, Evans J, Smeeth L, Henshaw K. Photodynamic therapy for neovascular age‐related macular degeneration. Cochrane Database of Systematic Reviews 2007, Issue 3. Art. No: CD002030. DOI: 10.1002/14651858.CD002030.pub3.
   Google Scholar
• De jong PT. Age‐related macular degeneration. N Engl J Med 2006; 355: 1474–1485.
   PubMed Web of Science ®Google Scholar
• Scholl HP, Fleckenstein M, Charbel issa P, Kielhauer C, Holz FG, Weber BH. An update on the genetics of age‐related macular degeneration. Mol Vis 2007; 13: 196–205.
   PubMed Web of Science ®Google Scholar
• Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000; 6: 389–395.
   PubMed Web of Science ®Google Scholar
• Shima DT, Adamis AP, Ferrara N, Yeo KT, Yeo TK, Allende R, Folkman J, D'amore PA. Hypoxic induction of endothelial cell growth factors in retinal cells: identification and characterization of vascular endothelial growth factor (VEGF) as the mitogen. Mol Med 1995; 1: 182–193.
   PubMed Web of Science ®Google Scholar
• Kvanta A. Ocular angiogenesis: the role of growth factors. Acta Ophthalmol Scand 2006; 84: 282–288.
   PubMedGoogle Scholar
• Zhou J, Pham L, Zhang N, He S, Gamulescu MA, Spee C, Ryan SJ, Hinton DR. Neutrophils promote experimental choroidal neovascularisation. Mol Vis 2005; 11: 414–424.
   PubMed Web of Science ®Google Scholar
• Vinores SA, Xiao WH, Aslam S, Shen J, Oshima Y, Nambu H, Liu H, Carmeliet P, Campochiard PA. Implication of the hypoxia response element of the VEGF promoter in mouse models of retinal and choroidal neovascularisation, but not retinal vascular development. J Cell Physiol 2005; 206: 749–758.
   Web of Science ®Google Scholar
• Petrova TV, Makinen T, Alitalo K. Signalling via vascular endothelial growth factor receptors. Exp Cell Res 1999; 253: 117–130.
   PubMed Web of Science ®Google Scholar
• Frank RN, Armin RH, Eliott D, Puklin JE, Abrams GW. Basic fibroblast growth factor and vascular endothelial growth factor are present in epiretinal and choroidal neovascular membranes. Am J Ophthalmol 1996; 122: 393–403.
   PubMed Web of Science ®Google Scholar
• Kvanta A, Algvere PV, Berglin L, Seregard S. Subfoveal fibrovascular membranes in age‐related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci 1996; 37: 1929–1934.
   PubMed Web of Science ®Google Scholar
• Kliffen M, Sharma HS, Mooy CM, Kerkvliet S, De jong PT. Increased expression of angiogenic growth factors in age‐related maculopathy. Br J Ophthalmol 1997; 81: 154–162.
   PubMed Web of Science ®Google Scholar
• Ishibashi T, Hata Y, Yoshikawa H, Nakagawa K, Sueishi K, Inomata H. Expression of vascular endothelial growth factor in experimental choroidal neovascularisation. Graefes Arch Clin Exp Ophthalmol 1997; 235: 159–167.
   PubMed Web of Science ®Google Scholar
• Krzystolik MG, Afshari M, Adamis AP, Gaudreault J, Gragoudas ES, Michaud NA, Li W, Connelly E, O'neill CA, Miller JW. Prevention of experimental choroidal neovascularisation with intravitreal anti‐vascular endothelial growth factor antibody fragment. Arch Ophthalmol 2002; 120: 338–346.
   PubMed Web of Science ®Google Scholar
• Gragoudas ES, Adamis AP, Cunningham ET, Feinsod M, Guyer DR; VEGF Inhibition Study in Ocular Neovascularization Clinical Trial group. Pegaptanib for neovascular age‐related macular degeneration. N Engl J Med 2004; 351: 2805–2816.
   PubMed Web of Science ®Google Scholar
• VEGF Inhibition Study In Ocular Neovascularization (VISION) Clinical Trial Group. Year 2 efficacy results of 2 randomised controlled clinical trials of pegaptanib for neovascular age‐related macular degeneration. Ophthalmology 2006; 113: 1508–1521.
   PubMed Web of Science ®Google Scholar
• Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY; MARINA Study Group. Ranibizumab for neovascular age‐related macular degeneration. New Engl J Med 2006; 355: 1419–1431.
   PubMed Web of Science ®Google Scholar
• Presta LG, Chen H, O'connor SJ, Chisholm V, Meng YG, Krummen L, Winkler M, Ferrara N. Humanization of a vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997; 57: 4593–4599.
   PubMed Web of Science ®Google Scholar
• Chen Y, Wiesmann C, Fuh G, Li B, Christinger HW, Mckay P, De vos AM, Lowman HB. Selection and analysis of an optimised anti‐VEGF antibody: crystal structure of an affinity‐matured Fab in complex with antigen. J Mol Biol 1999; 293: 865–881.
   PubMed Web of Science ®Google Scholar
• Muller YA, Chen Y, Christinger HW, Cunningham BC, Lowman HB, De vos AM. VEGF and the Fab fragment of a humanized neutralizing antibody: crystal structure of the complex at 2.4 A resolution and mutational analysis of the interface. Structure 1998; 6: 1153–1167.
   PubMed Web of Science ®Google Scholar
• Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S; ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age‐related macular degeneration. N Engl J Med 2006; 355: 1432–1444.
   PubMed Web of Science ®Google Scholar
• June 6, 2007 Pharmaceutical Benefits Scheme press release: http://www.pbs.gov.au/html/healthpro/news/article?id=NEWS‐2007‐06‐06‐ListingofLucentis.xml (accessed 20 December 2007).
   Google Scholar
• Dafer RM, Schneck M, Friberg TR, Jay WM. Intravitreal Ranibizumab and Bevacizumab: A review of risk. Semin Ophthalmol 2007; 22: 201–204.
   PubMedGoogle Scholar
• Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti‐VEGF antibody for treating cancer. Nat Rev Drug Discov 2004; 3: 391–400.
   PubMed Web of Science ®Google Scholar
• Mordenti J, Cuthebertson RA, Ferrara N, Thomson K, Berleau L, Licko V, Allen PC, Valverde CR, Meng YG, Fei DT, Fourre KM, Ryan AM. Comparisons of the intra‐ocular tissue distribution, pharmacokinetics, and safety of 125I‐labelled full‐length and Fab antibodies in rhesus monkeys following intravitreal administration. Toxicol Pathol 1999; 27: 536–544.
   PubMed Web of Science ®Google Scholar
• Heiduschka P, Fietz H, Hofmeister S, Schultheiss S, Mack AF, Peters S, Ziemssen F, Niggerman B, Julien S, Barz‐schmidt KU, Schraermeyer U; Tübingen Bevacizumab Study group. Penetration of bevacizumab through the retina following intravitreal injection in the monkey. Invest Ophthalmol Vis Sci 2007; 48: 2814–2823.
   PubMed Web of Science ®Google Scholar
• Shahar J, Avery RL, Heilweil G, Barak, A, Zemel E, Lewis GP, Johnson PT, Fisher SK, Perlman I, Loewenstein A. Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina 2006; 26: 262–269.
   PubMed Web of Science ®Google Scholar
• Michels S, Rosenfeld PJ, Puliafito CA, Marcus EN, Venkatraman AS. Systemic bevacizumab (Avastin) therapy for neovascular age‐related macular degeneration twelve‐week results of an uncontrolled open‐label clinical study. Ophthalmology 2005; 112: 1035–1047.
   PubMed Web of Science ®Google Scholar
• Moshfeghi AA, Rosenfeld PJ, Puliafito CA, Michels S, Marcus EN, Lenchus JD, Venkatraman AS. Systemic bevacizumab (Avastin) therapy for neovascular age‐related macular degeneration twenty‐four‐week results of an uncontrolled open‐label clinical study. Ophthalmology 2006; 113: 2002. e1–12.
   PubMed Web of Science ®Google Scholar
• Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography after intravitreal injection of bevacizumab for neovascular age‐related macular degeneration. Ophthalmic Surg Lasers Imaging 2005; 36: 331–335.
   PubMed Web of Science ®Google Scholar
• Gaudreault J, Fei D, Rusit J, Suboc P, Shiu V. Preclinical pharmacokinetics of ranibizumab (rhuFab V2) after a single intravitreal administration. Invest Ophthalmol Vis Sci 2005; 46: 726–733.
   PubMed Web of Science ®Google Scholar
• Lucentis full prescribing information: http://www.gene.com/gene/products/information/tgr/lucentis/insert.jsp (accessed 20 December 2007).
   Google Scholar
• Beer PM, Wong SJ, Hammad AM, Falk NS, O'malley MR, Khan S. Vitreous levels of unbound bevacizumab and unbound vascular endothelial growth factor in two patients. Retina 2006; 26: 871–876.
   PubMed Web of Science ®Google Scholar
• Gordon MS, Margolin K, Talpaz M, Sledge GW Jr, Holmgren E, Benjamin R, Stalters S, Shak S, Adelman D. Phase I safety and pharmacokinetic study of recombinant human anti‐vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001; 19: 843–850.
   PubMed Web of Science ®Google Scholar
• Ferrara N, Damico L, Shams N, Lowman H, Kim R. Development of ranibizumab, an anti‐vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age related neovascular macular degeneration. Retina 2006; 26: 859–870.
   PubMed Web of Science ®Google Scholar
• Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ. Intravitreal bevacizumab (Avastin) for neovascular age‐related macular degeneration. Ophthalmology 2006; 113: 363–372.
   PubMed Web of Science ®Google Scholar
• IVAN trial website: http://www.ivan‐trial.co.uk/; (accessed 20 December 2007).
   Google Scholar
• National Institute of Health and National Eye Institute Press Release Friday February 22, 2008. Comparison of AMD Treatments Trial: Lucentis—Avastin Trial. http://www.nih.gov/news/health/feb2008/nei‐22.htm; (accessed 29 April 2008).
   Google Scholar
• Schmidt‐erfurth UM, Richard G, Augustin A, Aylward WG, Bandello F, Corcostequi B, Cunha‐vaz J, Gaudric A, Leys A. Schlingemann RO; European Society for Retina Specialty Guidelines Committee. Guidance for the treatment of neovascular age‐related macular degeneration. Acta Ophthalmol Scand 2007; 85: 486–494.
   PubMedGoogle Scholar
• Genentech Press Release, 2 June 2006. Preliminary results from a phase iiib study showed patients with wet AMD treated with Lucentis quarterly experienced a 16‐letter benefit over the control group at one year. http://www.gene.com/gene/news/press‐releases/display.do?method=detail&id=9747&categoryid=4 (accessed December 20, 2007).
   Google Scholar
• Fung AE, Lalwani GA, Rosenfeld PJ, Dubovy SR, Michels S, Feuer WJ, Puliafito CA, Davis JL, Flynn HW Jr, Esquiabro M. An optical coherence tomography‐guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age‐related macular degeneration. Am J Ophthalmol 2007; 143: 566–183.
   PubMed Web of Science ®Google Scholar
• VEGF Inhibition Study In Ocular Neovascularization (VISION) Clinical Trial Group. Pegaptanib sodium for neovascular age‐related macular degeneration: two‐year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology 2006; 113: 992–1001.
   Web of Science ®Google Scholar
• Results of the Endophthalmitis Vitrectomy Study. A randomized trial of immediate vitrectomy and of intravenous antibiotics for the treatment of postoperative bacterial endophthalmitis. Endophthalmitis Vitrectomy Study Group. Arch Ophthalmol 1995; 113: 1479–1496.
   PubMedGoogle Scholar
• Ferrara N. Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am J Cell Physiol 2001; 280: C1358–C1366.
   PubMed Web of Science ®Google Scholar
• Ratner M. Genentech discloses safety concerns over Avastin. Nat Biotechnol 2004; 22: 1198.
   PubMed Web of Science ®Google Scholar
• Van wijngaarden P, Coster DJ, Williams KA. Inhibitors of ocular neovascularisation. Promises and potential problems. JAMA 2005; 293: 1509–1513.
   PubMed Web of Science ®Google Scholar
• Gilles MC. What we don't know about Avastin might hurt us. Arch Ophthalmol 2006; 124: 1478–1479.
   Google Scholar
• Wong TY, Klein R, Sun C, Mitchell P, Couper DJ, Lai H, Hubbard LD, Sharrett AR; Arteriosclerosis Risk in Communities Study. Age‐related macular degeneration and risk for stroke. Ann Int Med 2006; 145: 98–106.
   PubMed Web of Science ®Google Scholar
• Duan Y, Mo J, Klein R, Scott IU, Lin HM, Caulfield J, Patel M, Liao D. Age‐related macular degeneration is associated with incident myocardial infarction among elderly Americans. Ophthalmology 2007; 114: 732–737.
   PubMed Web of Science ®Google Scholar
• Wong TY, Tikellis G, Sun C, Klien R, Couper DJ, Sharrett AR. Age‐related macular degeneration and risk of coronary heart disease: the Atherosclerosis Risk in Communities Study. Ophthalmology 2007; 114: 86–91.
   PubMed Web of Science ®Google Scholar
• Cugati S, Cumming RG, Smith W, Burlutsky G, Mitchell P, Wang JJ. Visual impairment, age‐related macular degeneration, cataract and long‐term mortality: the Blue Mountains Eye Study. Arch Ophthalmol 2007; 125: 917–924.
   PubMedGoogle Scholar
• Genentech. Safety update on Lucentis. Jan 24, 2007. http://www.fda.gov/medwatch/safety/2007/Lucentis_DHCP_01‐24‐2007.pdf (accessed 20 December 2007).
   Google Scholar
• Gilles MC, Wong TY. Ranibizumab for the treatment of neovascular age‐related macular degeneration. N Engl J Med 2007; 356: 748–749.
   Google Scholar
• Manzano RPA, Peyman GA, Khan P, Kivilcim M. Testing intravitreal toxicity of bevacizumab (Avastin). Retina 2006; 26: 257–261.
   PubMed Web of Science ®Google Scholar
• Feiner L, Barr EE, Shui YB, Holekamp NM, Brantley MA Jr. Safety of intravitreal injection of bevacizumab in rabbit eyes. Retina 2006; 26: 882–888.
   PubMed Web of Science ®Google Scholar
• Bakri SJ, Cameron JD, Mccannel CA, Pulido JS, Marler RJ. Absence of histologic retinal toxicity of intravitreal bevacizumab in a rabbit model. Am J Ophthalmol 2006; 142: 162–164.
   PubMed Web of Science ®Google Scholar
• Fung AE, Rosenfeld PJ, Reichel E. The International Intravitreal Bevacizumab Safety Survey: Using the internet to assess drug safety worldwide. Br J Ophthalmol 2006: 90: 1344–1349.
   PubMed Web of Science ®Google Scholar
• Ziemssen F, Grisanti S, Bartz‐schmidt KU. The international intravitreal bevacizumab safety survey. Br J Ophthalmol 2006; 90: 1440–1441.
   Web of Science ®Google Scholar
• Wu L, Martinez‐castellanos MA, Quiroz‐mercado H, Arevola JF, Berrocal MJ, Farah ME, Maia M, Rodriquez FJ. Pan American Collaborative Retina Group (PACORES). Twelve‐month safety of intravitreal injections of bevacizumab (Avastin) results of the Pan‐American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol 2008; 246: 81–87.
   PubMed Web of Science ®Google Scholar
• Storkebaum E, Lambrechts D, Carmeliet P. VEGF: once regarded as a specific angiogenic factor, now implicated in neuroprotection. Bioessays 2004; 26: 943–954.
   PubMed Web of Science ®Google Scholar
• Inan UU, Avci B, Kusbecy T, Kaderli B, Avci R, Temet SG. Preclinical safety evaluation of intravitreal injection of full‐length humanized vascular endothelial growth factor antibody in rabbit eyes. Invest Ophthalmol Vis Sci 2007; 48: 1773–1781.
   PubMed Web of Science ®Google Scholar
• Peters S, Heiduschka P, Julien S, Ziemssen F, Fietz H, Bartz‐schmidt KU; Tübingen Bevacizumab Study Group. Ultrastructural findings in the primate eye after intravitreal injection of bevacizumab. Am J Ophthalmol 2007; 143: 995–1002.
   PubMed Web of Science ®Google Scholar
• Klaver CC, Assink JJ, Van leeuwen R, Wolfs CC, Vingerling JR, Stijnan T, Hofman A, De jong PT. Incidence and progression rates of age‐related maculopathy: the Rotterdam Eye Study. Invest Ophthalmol Vis Sci 2001; 42: 2237–2241.
   PubMed Web of Science ®Google Scholar
• Thornton J, Edwards R, Mitchell P, Harrison RA, Buchan I, Kelly SP. Smoking and age‐related macular degeneration: a review of association. Eye 2005; 19: 935–944.
   PubMed Web of Science ®Google Scholar
• Tan JS, Mitchell P, Kifley A, Flood V, Smith W, Wang JJ. Smoking and the long‐term incidence of age‐related macular degeneration: the Blue Mountains Eye Study. Arch Ophthalmol 2007. 125: 1089–1095.
   PubMedGoogle Scholar
• Chong EW, Wong TY, Kries AJ, Simpson JA, Guymer RH. Dietary antioxidants and the primary prevention of age related macular degeneration: systematic review and meta‐analysis. Br Med J 2007; 335 (7623): 755.
   PubMed Web of Science ®Google Scholar
• Age‐Related Eye Disease Study Research Group. A randomized, placebo‐controlled, clinical trial of high dose supplementation with vitamins C and E, beta carotene, and zinc for age‐related macular degeneration and vision loss: AREDS report no. 8Arch Ophthalmol 2001; 119: 1417–1436.
   PubMed Web of Science ®Google Scholar
• Evans JR. Antioxidant vitamin and mineral supplements for slowing the progression of age‐related macular degeneration. Cochrane Database Syst Rev 2006; 4: CD000254.
   Google Scholar
• Alpha‐Tocopherol, Beta‐carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. New Engl J Med 1994; 330: 1029–1035.
   PubMed Web of Science ®Google Scholar
• Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen MR, Glass A, Keogh JP, Meyskens FL, Valanis B, Williams JH, Barnhart S, Hammar S. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. New Engl J Med 1996; 334: 1150–1155 and 1189–1190.
   PubMed Web of Science ®Google Scholar
• The HOPE and HOPE‐TOO trial investigators. The effects of long term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA 2005; 293: 1338–1347.
   PubMed Web of Science ®Google Scholar
• Spaide RF, Laud K, Fine HF, Klancnik JM Jr, Meyerle CB, Yannuzzi LA, Sorenson J, Slakter J, Fisher YL, Cooney MJ. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age‐related macular degeneration. Retina 2006; 26: 383–390.
   PubMed Web of Science ®Google Scholar
• Avery R, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ. Intravitreal bevacizumab (Avastin) for neovascular age‐related macular degeneration. Ophthalmology 2006; 113: 363–372.
   PubMed Web of Science ®Google Scholar
• Rich RM, Rosenfeld PJ, Puliafito CA, Dubovy SR, Davis JL, Flynn HW, Gonzalez S, Feuer WJ, Lin RC, Lalwani GA, Nguyen JK, Kumar G. Short‐term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age‐related macular degeneration. Retina 2006; 26: 495–511.
   PubMed Web of Science ®Google Scholar
• Chen CY, Wong TY, Heriot WJ. Intravitreal bevacizumab (Avastin) for neovascular age‐related macular degeneration: a short‐term study. Am J Ophthalmol 2007; 143: 510–512.
   PubMed Web of Science ®Google Scholar